Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...
Read Full NewsNew York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.
The drug was previously approved for stage 2 T1D.
Findings suggest young females should be assessed and, if at risk, monitored.
Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.
Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.
The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.
Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.
1.
Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.
2.
Top Options Are Discovered Through Direct Comparison of 25 Migraine Drugs.
3.
Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.
4.
A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.
5.
EBCC: European Breast Cancer Conference
1.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
2.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
3.
Patient-Centric Approaches in Hematology: Integrating Individualized Care into Modern Clinical Practice
4.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
5.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
2.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
4.
Current Scenario of Cancer- Q&A Session to Close the Gap
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge